Overview
Eli Lilly has entered a $2.75 billion collaboration with Insilico Medicine focused on AI-driven drug discovery. This partnership aims to enhance Lilly's research pipeline by integrating AI technologies, addressing the growing competition in high-growth therapeutic areas.
Products
Loading...
Recent Deals
Eli Lilly has entered a $2.75 billion collaboration with Insilico Medicine focused on AI-driven drug discovery. This partnership aims to enhance Lilly's research pipeline by integrating AI technologies, addressing the growing competition in high-growth therapeutic areas.
Insilico Medicine, a clinical-stage biotechnology company, has entered a co-development collaboration with Hygtia Therapeutics for its ISM8969 program, a brain-penetrant NLRP3 inhibitor targeting CNS disorders. Insilico is set to receive up to $66 million in payments, including an initial $10 million upfront. The partnership aims to advance the clinical development of ISM8969, which shows promise in treating neuroinflammation-related diseases like Parkinson's and Alzheimer's.
Insilico Medicine has entered a multi-year collaboration with Servier, focusing on the discovery and development of novel oncology therapies. The partnership leverages Insilico's AI-driven drug discovery platform, pharma.ai, alongside Servier's expertise in cancer drug development, with a potential value of up to $888 million.